EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction | European Urology | 2013 | 808 |
The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia | European Urology | 2013 | 103 |
Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial | Journal of the American Geriatrics Society | 2013 | 81 |
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms | European Urology | 2013 | 67 |
Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma | British Journal of Cancer | 2013 | 65 |
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies | Urology | 2013 | 47 |
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy | World Journal of Urology | 2013 | 43 |
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study | Journal of Sexual Medicine | 2013 | 41 |
Laparoendoscopic single-site partial nephrectomy: a multi-institutional outcome analysis | European Urology | 2013 | 33 |
Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties | Therapeutic Advances in Urology | 2013 | 32 |
Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence | World Journal of Urology | 2013 | 30 |
High CRP values predict poor survival in patients with penile cancer | BMC Cancer | 2013 | 29 |
Review on ultrasound measurement of bladder or detrusor wall thickness in women: techniques, diagnostic utility, and use in clinical trials | World Journal of Urology | 2013 | 26 |
Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder | Medical Oncology | 2013 | 25 |
Perspectives on treatment of metastatic castration-resistant prostate cancer | Oncologist | 2013 | 24 |
Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma | BMC Cancer | 2013 | 22 |
The role of phosphodiesterases in bladder pathophysiology | Nature Reviews Urology | 2013 | 22 |
Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC) | British Journal of Cancer | 2013 | 22 |
Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy | Urologic Oncology: Seminars and Original Investigations | 2013 | 21 |
Phosphodiesterase inhibitors in clinical urology | Expert Review of Clinical Pharmacology | 2013 | 20 |
Elevated C-reactive protein values predict nodal metastasis in patients with penile cancer | BMC Urology | 2013 | 20 |
Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study | International Journal of Urology | 2013 | 19 |
The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction | Research and Reports in Urology | 2013 | 15 |
Laparoendoscopic single-site nephroureterectomy for upper urinary tract urothelial carcinoma: outcomes of an international multi-institutional study of 101 patients | BJU International | 2013 | 14 |
PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH | Current Bladder Dysfunction Reports | 2013 | 12 |